PM200 Australian Experience with AbsorbTM Bioresorbable Scaffold Technology in "Real-World" Coronary Disease

Abstract

Introduction: Coronary metallic stents have been the cornerstone of treatment for coronary arterial disease. Bioabsorbable coronary scaffolds represent a novel treatment option that allows the initial restoration of coronary flow and support of the vessel, however with subsequent resorption of the scaffold, the risks of stent thrombosis and need for longterm antiplatelet therapy can be potentially reduced. “Real world” data on the use of this technology in a more complex subset of patients and lesions is lacking. Objectives: We aimed to study the safety and efficacy of the Absorb bioabsorbable scaffold (ABRS) out to 30 days for the treatment of patients presenting with acute coronary syndrome (ACS) and stable angina, in a wide range of lesion subsets including primary PCI, chronic total occlusions (CTOs), bifurcations, long lesions and multi-vessel disease. Methods: Data was prospectively collected from 3 major tertiary hospitals in Australia (Fremantle Hospital, Western Australia, and Prince of Wales Public Hospital and Sutherland Hospital, New South Wales) between December 2010 and August 2013. Baseline demographics, presentation, as well as procedural data were collected. Both in-hospital and 30 day safety and efficacy outcomes were analysed. Results: In total, 155 patients were treated with 245 scaffolds (mean age 60yrs, 60% male) with 52% presenting with ACS (6% STEMI) and 10% undergoing multi-vessel intervention. There was a mean of 1.6 scaffolds/patient (range 1 to 5) with LAD, LCX, RCA and SVG treated in 39%, 22%, 35%, and 2.3% respectively. There was 100% procedural success and 99% device success (2 device delivery failures with subsequent successful treatment with drug-eluting stents). There were 2 in-hospital myocardial infarcts (Non Q wave, 1.3%) with no mortality. At 30 days, there were a total of 3 myocardial infarcts (1.9%) including 1 scaffold thrombosis (0.6%) requiring target vessel revascularization (0.6%). There was no mortality. Conclusion: This early local experience has demonstrated ABRS therapy to be highly safe and efficacious in a cohort of real-world patients with complex presentations and disease (including ACS, long lesions, multi-vessel disease and CTOs). Disclosure of Interest: None Declared